Clinical trial · Interventional
Hypofractionated Radiotherapy for Recurrent DIPG
Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma
NCT03841435CI-TRIAL-00069521completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the feasibility of hypofractionated radiotherapy (RT) in the palliative treatment of recurrent diffuse intrinsic pontine glioma (DIPG). Participants will receive 15 Gy in 3 fractions as opposed to the standard 20 Gy in 10 fractions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Diffuse Intrinsic Pontine Glioma | Diffuse Intrinsic Pontine Glioma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hypofractionated Radiotherapy
- description
- 15 Gy given in 3 fractions over 2 weeks
- interventionNames
- Radiation: Hypofractionated Radiotherapy
Primary outcomes (1)
- measure
- Post Radiation Toxicity
- timeFrame
- Through Study Completion, an average of 1 year
- description
- RTOG common toxicity criteria grade 0-5
Secondary outcomes (5)
- measure
- Change in Quality of Life score
- timeFrame
- Pre-RT, 2 weeks, 1 month, 3 months and every 3 months there-after post RT
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients must be ≤30 years of age 2. Patients must have a diagnosis of progressive DIPG. 3. Received prior IMRT based definitive radiotherapy to a dose of ≥54 Gy. 4. The patient and or parent/legal guardian must be physically and mentally capable of signing the consent form of their own volition. 5. Steroids dosage must be unchanged for 5 days. 6. No Bevacizumab within 21 days (Half-life 11 days \~) Exclusion Criteria: 1. Patients with incomplete medical records 2. Patients with prior history of reirradiation for DIPG 3. Life expectancy \< or equal to 1 month 4. Pregnant women 5. Age \>30 6. Prisoners 7. Concurrent systemic therapy at the time of reirradiation 8. Physically or mentally incapable of signing the consent form of their own volition 9. \< 6 mos time interval between completion of initial RT to start of reRT.
References
Publications (17)
- BACKGROUNDOstrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013 Nov;15 Suppl 2(Suppl 2):ii1-56. doi: 10.1093/neuonc/not151. No abstract available. PMID 24137015
- BACKGROUNDVanan MI, Eisenstat DD. DIPG in Children - What Can We Learn from the Past? Front Oncol. 2015 Oct 21;5:237. doi: 10.3389/fonc.2015.00237. eCollection 2015. PMID 26557503
- BACKGROUNDFangusaro J. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol. 2009 Nov;24(11):1409-17. doi: 10.1177/0883073809338960. Epub 2009 Jul 28. PMID 19638636
- BACKGROUNDFontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, Wolff JE, Mahajan A. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012 Feb;35(1):51-7. doi: 10.1097/COC.0b013e318201a2b7. PMID 21297433
- BACKGROUNDMerchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):87-97. doi: 10.1016/j.ijrobp.2007.09.037. PMID 18406885
- BACKGROUNDLiu AK, Foreman NK, Gaspar LE, Trinidad E, Handler MH. Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children. Pediatr Blood Cancer. 2009 Jul;52(7):804-7. doi: 10.1002/pbc.21982. PMID 19260098
- BACKGROUNDBouffet E, Hawkins CE, Ballourah W, Taylor MD, Bartels UK, Schoenhoff N, Tsangaris E, Huang A, Kulkarni A, Mabbot DJ, Laperriere N, Tabori U. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1541-8. doi: 10.1016/j.ijrobp.2011.10.039. Epub 2012 Jan 13.